Skip to main content
SpringerLink
Log in
Book cover

Malignant lymphomas, including Hodgkin’s disease: Diagnosis, management, and special problems pp 21–36Cite as

Timing of bone marrow transplantation in therapy of Hodgkin’s disease

  • Chapter

  • 37 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 66))

Abstract

Thirty years ago, few patients with advanced Hodgkin’s disease could expect to be alive and free of disease 5 years from the time of diagnosis [1]. Now at least 50% of such patients can expect to be cured using frontline combination chemotherapy regimens [2–7]. Nonetheless, a substantial proportion of patients remain who either fail to achieve an initial remission or who relapse after attaining a remission. These patients have a poor outlook without effective salvage therapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aisenberg AC, Qazi R: Improved survival in Hodgkin’s disease. Cancer 37:2423–2429, 1976.

    Article  PubMed  CAS  Google Scholar 

  2. Bakemeier RF, Anderson JR, Costello W, et al.: BCVPP chemotherapy for advanced Hodgkin’s disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Ann Intern Med 101:447–456, 1984.

    PubMed  CAS  Google Scholar 

  3. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 104:739–746, 1986.

    PubMed  CAS  Google Scholar 

  4. Longo DL, Young RC, Wesley M, et al.: Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4:1295–1306, 1986.

    PubMed  CAS  Google Scholar 

  5. Santoro A, Bonadonna G, Valagussa P, et al.: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27–37, 1987.

    PubMed  CAS  Google Scholar 

  6. Klimo P, Connors JM: An update on the Vancouver experience in the management of advanced Hodgkin’s disease treated with the MOPP/ABV hybrid program. Semin Hematol 25(Suppl 2):34–40, 1988.

    PubMed  CAS  Google Scholar 

  7. Vose JM, Bierman PJ, Anderson JR, et al.: CHLVPP chemotherapy with involved-field irradiation for Hodgkin’s disease: favorable results with acceptable toxicity. J Clin Oncol 9:1421–1425, 1991.

    PubMed  CAS  Google Scholar 

  8. Gratwohl A: Bone marrow transplantation activity in Europe 1990. Bone Marrow Transpl 8:197–201, 1991.

    CAS  Google Scholar 

  9. Gorin NC, Gale RP, Armitage JO: Autologous bone marrow transplants: different indications in Europe and North America. Lancet 2:317–318, 1989.

    Google Scholar 

  10. Bone-marrow autotransplantation in man: report of an international cooperative study. Lancet 2:960–962, 1986.

    Google Scholar 

  11. Fox KA, Lippman SM, Cassady JR, et al.: Radiation therapy salvage of Hodgkin’s disease following chemotherapy failure. J Clin Oncol 5:38–45, 1987.

    PubMed  CAS  Google Scholar 

  12. Mauch P, Tarbell N, Skarin A, et al.: Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 5:544–549, 1987.

    PubMed  CAS  Google Scholar 

  13. Roach M III, Kapp DS, Rosenberg SA, et al.: Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol 5:550–555, 1987.

    PubMed  Google Scholar 

  14. Lohri A, Barnett M, Fairey RN, et al.: Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77:2292–2298, 1991.

    PubMed  CAS  Google Scholar 

  15. Buzaid AC, Lippman SM, Miller TP: Salvage therapy of advanced Hodgkin’s disease: critical appraisal of curative potential. Am J Med 83:523–532, 1987.

    Article  PubMed  CAS  Google Scholar 

  16. Canellos GP: Is there an effective salvage therapy for advanced Hodgkin’s disease? Ann Oncol 2(Suppl l):l–7, 1991.

    Google Scholar 

  17. Longo DL, Duffey PL, Young RC, et al.: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218, 1992.

    PubMed  CAS  Google Scholar 

  18. Bonadonna G, Santoro A, Gianni AM, et al.: Primary and salvage chemotherapy in advanced Hodgkin’s disease: the Milan Cancer Institute experience. Ann Oncol 2(Suppl 1):9–16, 1991.

    Article  PubMed  Google Scholar 

  19. Fisher RI, DeVita VT, Hubbard SP, et al.: Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763, 1979.

    PubMed  CAS  Google Scholar 

  20. Harker WG, Kushlan P, Rosenberg SA: Combination chemotherapy for advanced Hodgkin’s disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 101:440–446, 1984.

    PubMed  CAS  Google Scholar 

  21. Viviani S, Santoro A, Negretti E, et al.: Salvage chemotherapy in Hodgkin’s disease. Ann Oncol 1:123–127, 1990.

    PubMed  CAS  Google Scholar 

  22. Armitage JO, Bierman PJ, Vose JM, et al.: Autologous bone marrow transplantation for patients with relapsed Hodgkin’s disease. Am J Med 91:605–611, 1991.

    Article  PubMed  CAS  Google Scholar 

  23. Jagannath S, Armitage JO, Dicke KA, et al.: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 7:179–185, 1989.

    PubMed  CAS  Google Scholar 

  24. Reece DE, Barnett MJ, Connors JM, et al.: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 9:1871–1879, 1991.

    PubMed  CAS  Google Scholar 

  25. Kessinger A, Bierman PJ, Vose JM, et al.: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin’s disease. Blood 77:2322–2325, 1991.

    PubMed  CAS  Google Scholar 

  26. Carella AM, Congiu AM, Gaozza E, et al.: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: an Italian study group report. J Clin Oncol 6:1411–1416, 1988.

    PubMed  CAS  Google Scholar 

  27. Gribben JG, Linch DC, Singer CRJ, et al.: Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340–344, 1989.

    PubMed  CAS  Google Scholar 

  28. Zulian GB, Selby P, Milan S, et al.: High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin’s disease. Br J Cancer 59:631–635, 1989.

    Article  PubMed  CAS  Google Scholar 

  29. Horning SJ, Chao NJ, Negrin RS, et al.: The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin’s disease and non-Hodgkin’s lymphoma: preliminary data. Ann Oncol 2(Suppl l):47–50, 1991.

    Article  PubMed  Google Scholar 

  30. Wheeler C, Antin JH, Churchill WH, et al.: Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: a dose-finding study. J Clin Oncol 8:648–656, 1990.

    PubMed  CAS  Google Scholar 

  31. Jones RJ, Piantadosi S, Mann RB, et al.: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 8:527–537, 1990.

    PubMed  CAS  Google Scholar 

  32. Haas R, Hohaus S, Egerer G, et al.: Autologous blood stem cell transplantation in relapsed Hodgkin’s disease. Int J Cell Cloning 10(Suppl 1):138–140, 1992.

    Article  Google Scholar 

  33. Phillips GL, Wolff SN, Herzig RH, et al.: Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73: 2086–2092, 1989.

    PubMed  CAS  Google Scholar 

  34. Moormeier JA, Williams SF, Kaminer LS, et al.: Autologous bone marrow transplantation followed by involved field radiotherapy in patients with relapsed or refractory Hodgkin’s disease. Leuk Lymphom 5:243–248, 1991.

    Article  Google Scholar 

  35. Ahmed T, Ciavarella D, Feldman E, et al.: High-dose, potentially myeloablative chemotherapy and autologous bone macrow transplantation for patients with advanced Hodgkin’s disease. Leukemia 3:19–22, 1989.

    PubMed  CAS  Google Scholar 

  36. Russell JA, Selby PJ, Ruether BA, et al.: Treatment of advanced Hodgkin’s disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transpl 4:425–429, 1989.

    CAS  Google Scholar 

  37. Yahalom J, Gulati S, Shank B, et al.: Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin’s disease. Int J Radiat Oncol Biol Phys 17:915–922, 1989.

    Article  PubMed  CAS  Google Scholar 

  38. Brandwein JM, Smith AM, Langley GR, et al.: Outcome of patients with relapsed or refractory non-Hodgkin’s lymphoma referred for autologous bone marrow transplantation. Blood 76(Suppl 1):530, 1990.

    Google Scholar 

  39. Philip T, Armitage JO, Spitzer G, et al.: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316:1493–1498, 1987.

    Article  PubMed  CAS  Google Scholar 

  40. Philip T, Hartmann O, Biron P, et al.: High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin’s lymphoma. J Clin Oncol 6:1118–1124, 1988.

    PubMed  CAS  Google Scholar 

  41. Gribben JG, Goldstone AH, Linch DC, et al.: Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin’s lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol 7:1621–1629, 1989.

    PubMed  CAS  Google Scholar 

  42. Gulati SC, Shank B, Black P, et al.: Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 6:1303–1313, 1988.

    PubMed  CAS  Google Scholar 

  43. Green ES, Taghipour G, Goldstone AH: Report of the EBMTG registry of ABMT in Hodgkin’s disease: outcome in patients followed for at least three years. Bone Marrow Transpl 5(Suppl 2):23, 1990.

    Google Scholar 

  44. Bierman PJ, Vose JM, Armitage JO: Chemotherapy sensitivity predicts a better outcome with high-dose therapy and autotransplantation in Hodgkin disease (HD). Proc Am Soc Clin Oncol 9:259, 1990.

    Google Scholar 

  45. Desch CE, Lasala MR, Smith TJ, et al.: The optimal timing of autologous bone marrow transplantation in Hodgkin’s disease patients after a chemotherapy relapse. J Clin Oncol 10:200–209, 1992.

    PubMed  CAS  Google Scholar 

  46. Nademanee A, Schmidt GM, O’Donnell MR, et al.: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 80:1130–1134, 1992.

    PubMed  CAS  Google Scholar 

  47. Straus DJ, Gaynor JJ, Myers J, et al.: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8:1173–1186, 1990.

    PubMed  CAS  Google Scholar 

  48. Proctor SJ, Taylor P, Donnan P, et al.: A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. Eur J Cancer 27:624–629, 1991.

    Article  PubMed  CAS  Google Scholar 

  49. Kuentz M, Reyes F, Brun B, et al.: Early response to chemotherapy as a prognostic factor in Hodgkin’s disease. Cancer 52:780–785, 1983.

    Article  PubMed  CAS  Google Scholar 

  50. Monconduit M, Tilly H, Menard JF, et al.: Prognostic value of response after three MOPP cycles in Hodgkin’s disease—stage III and IV. Blut 54:171–177, 1987.

    Article  PubMed  CAS  Google Scholar 

  51. Carella AM, Carlier P, Congiu A, et al.: Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin’s disease in fist complete remission after MOPP/ ABVD protocol. Bone Marrow Transpl 8:99–103, 1991.

    CAS  Google Scholar 

  52. Brandwein JM, Callum J, Sutcliffe SB, et al.: Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin’s disease. Bone Marrow Transpl 5:99–103, 1990.

    CAS  Google Scholar 

  53. Goldstone AH, Chopra R: Autografting in lymphoma: Prospects for the future. In Autologous Bone Marrow Transplantation. Proceedings of the Fifth International Symposium, Omaha, Nebraska, pp 551–561, 1990.

    Google Scholar 

  54. Taylor KM, Jagannath S, Spitzer G, et al.: Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin’s disease. J Clin Oncol 7:1791–1799, 1989.

    PubMed  CAS  Google Scholar 

  55. Gulati SC, Bennett CL: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 116:177–182, 1992.

    PubMed  CAS  Google Scholar 

  56. Hovgaard DJ, Nissen NI: Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin’s disease: a phase I/II study. J Clin Oncol 10:390–397, 1992.

    PubMed  CAS  Google Scholar 

  57. Tourani J-M, Levy R, Colonna P, et al.: High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin’s disease. J Clin Oncol 10:1086–1094, 1992.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Philip J. Bierman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health Sciences University, USA

    Bruce W. Dana (Clinical Associate Professor of Medicine, Member) (Clinical Associate Professor of Medicine, Member)

  2. The Hematology Clinic Portland, Oregon, USA

    Bruce W. Dana (Clinical Associate Professor of Medicine, Member) (Clinical Associate Professor of Medicine, Member)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bierman, P.J. (1993). Timing of bone marrow transplantation in therapy of Hodgkin’s disease. In: Dana, B.W. (eds) Malignant lymphomas, including Hodgkin’s disease: Diagnosis, management, and special problems. Cancer Treatment and Research, vol 66. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3084-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3084-8_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6347-7

  • Online ISBN: 978-1-4615-3084-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation